Clonal tree frequency analysis reveals affinity determinants and enables antibody lead optimization
- 1Biologics Engineering, Oncology, AstraZeneca R&D, Cambridge, UK
- 2Department of Microbes, Infection and Microbiomes, Institute of Microbiology and Infection, University of Birmingham, Birmingham, UK
- 3Respiratory & Immunology, Biopharmaceuticals, AstraZeneca R&D, Cambridge, UK
Abstract
Understanding the sequence determinants of antibody affinity within a clonal family is a central challenge in therapeutic antibody discovery. Here, we applied amino acid frequency analysis to a large phylogenetic clonal tree of anti-ST2 monoclonal antibodies, where V(D)J recombination is constant and only somatic hypermutations vary. We identified M33I and L100I in the heavy chain as key affinity-governing mutations, corroborated by AlphaFold2 structural modeling and molecular dynamics free‑energy decomposition. The I33/I100 genotype predicted significantly improved functional neutralization of IL-33-induced IL-6 release and was associated with a higher transcriptomic affinity score (Hiscore). Prospective mutagenesis of three low-affinity parent antibodies achieved up to 10-fold affinity improvement, establishing a workflow integrating sequence statistics, structural modeling, transcriptomics and MD simulation for rational lead optimization.
Related
- Optimal Maturation Protocols for High-Affinity Antibody Targets: A Path-Integral Approach
- CIR-DDG: backbone-agnostic residual correction of antibody-antigen affinity changes with explicit cross-chain geometry
- Antibody-Antigen Affinity Prediction with Chain-Aware Protein Language Modeling
- Model‐Informed First‐In‐Human Dose Selection for AZD2796, a High‐Affinity Anti‐LILRB2 Antibody
- A blinded, prospective benchmark of in silico antibody discovery anchored to experimental affinity and developability
BibTeX
@article{waterhouse2026clonal,
title = {{Clonal tree frequency analysis reveals affinity determinants and enables antibody lead optimization}},
author = {Mark Waterhouse and Shuang Gu and Maria Tsoumpeli and Ben Dugan and Karanjot Sandhu and Chiara Ciminieri and Zenon Zenonos and Suzanne Cohen and Darren J. Schofield and Xavier Romero-Ros and Michele Chirichella},
journal = {mAbs},
year = {2026},
month = nov,
doi = {10.1080/19420862.2026.2755659},
url = {https://doi.org/10.1080/19420862.2026.2755659},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - Clonal tree frequency analysis reveals affinity determinants and enables antibody lead optimization
AU - Mark Waterhouse
AU - Shuang Gu
AU - Maria Tsoumpeli
AU - Ben Dugan
AU - Karanjot Sandhu
AU - Chiara Ciminieri
AU - Zenon Zenonos
AU - Suzanne Cohen
AU - Darren J. Schofield
AU - Xavier Romero-Ros
AU - Michele Chirichella
PY - 2026
DA - 2026/11/04
JO - mAbs
DO - 10.1080/19420862.2026.2755659
UR - https://doi.org/10.1080/19420862.2026.2755659
AB - Understanding the sequence determinants of antibody affinity within a clonal family is a central challenge in therapeutic antibody discovery. Here, we applied amino acid frequency analysis to a large phylogenetic clonal tree of anti-ST2 monoclonal antibodies, where V(D)J recombination is constant and only somatic hypermutations vary. We identified M33I and L100I in the heavy chain as key affinity-governing mutations, corroborated by AlphaFold2 structural modeling and molecular dynamics free‑energy decomposition. The I33/I100 genotype predicted significantly improved functional neutralization of IL-33-induced IL-6 release and was associated with a higher transcriptomic affinity score (Hiscore). Prospective mutagenesis of three low-affinity parent antibodies achieved up to 10-fold affinity improvement, establishing a workflow integrating sequence statistics, structural modeling, transcriptomics and MD simulation for rational lead optimization.
SN - 1942-0862
SN - 1942-0870
ER -